What is the 13F Pro Quality Score for RGNX?

13F Pro ranks REGENXBIO Inc. (RGNX) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View RGNX's current score at https://13fpro.ai/research/RGNX (free sign-up required for the full ranking).

Which hedge funds own the most RGNX stock?

Based on the most recent Form 13F-HR filings on SEC EDGAR, the largest reported institutional holders of RGNX include BlackRock,, Redmile Group,, STATE STREET. Holdings are reported quarterly within 45 days of quarter-end and updated on https://13fpro.ai/research/RGNX as soon as new 13F filings post.

Where does 13F Pro source RGNX data?

All REGENXBIO Inc. fundamentals and ownership data come directly from SEC EDGAR. REGENXBIO Inc. files with the SEC under CIK 1590877. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is RGNX in?

REGENXBIO Inc. (RGNX) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is RGNX research updated on 13F Pro?

RGNX's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

REGENXBIO Inc.(RGNX)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1590877 RGNX stock profile & AI dashboard →

13F Pro Quality Score

26.9/100

Rank #2,487 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

88.4/100

Profitability

6.3/100

Balance Sheet

3.6/100

Earnings Quality

30.0/100

Free Cash Flow

6.7/100

Institutional Flow

27.8/100

Revenue Scale

20.8/100

Dilution Risk

9.1/100

RGNX Stock Analysis & AI Quality Score

AI stock analysis and institutional research for REGENXBIO Inc. (RGNX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores RGNX at 26.9/100 on a 32-signal composite quality model, placing it at rank #2,487 of 2,879 stocks — the bottom half of the AI-ranked universe. RGNX scores in the top quartile across revenue growth (88.4). Areas of concern include balance sheet strength (3.6) and profitability (6.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 9.1/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), REGENXBIO Inc. reports quarterly revenue of $6.4M, net income of $-90.1M, free cash flow of $-77.4M. Top institutional holders of RGNX by reported 13-F value include BlackRock,, Redmile Group,, STATE STREET, based on the most recent SEC filings. RGNX trades on the Nasdaq exchange and files with the SEC under CIK 1590877. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate RGNX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for REGENXBIO Inc. directly from SEC EDGAR. REGENXBIO Inc.'s 13F Pro composite quality score has ranged between 8 and 43 since 2021, currently 26.9 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.

✦

Fun facts about REGENXBIO Inc.

Quirks, history, and lore behind RGNX — the kind of stuff that makes a stock memorable.

1
The Basics
U.S. biotechnology company · small-cap · listed on Nasdaq · headquartered in Maryland.
2
The Numbers
Annual revenues in the low tens of millions, typical of a clinical-stage biotech — the real value sits in the pipeline, not the income statement.
3
The History
Founded in the 2010s, it was built around a landmark academic breakthrough in gene therapy vectors licensed from the University of Pennsylvania.
4
The Secret
Its crown jewel isn't a drug — it's a patent licensing platform for NAV Technology, collecting royalties from other gene therapy companies who need its delivery tools.
5
The Lore
Its licensees include some of the biggest names in gene therapy, meaning this small Maryland outfit quietly collects a toll every time a blockbuster gene therapy gets sold — anywhere in the world.
6
The Giveaway
The ticker spells out exactly what it does: regenerate with next-generation adeno-associated virus (AAV) vectors — this is the company that built the NAV Technology Platform and licenses it to the gene therapy universe.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$6.4M

Net Income

Q1 2026

$-90.1M

Free Cash Flow

Q1 2026

$-77.4M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+104.5% YoY

$170.4MFY 2025

FY22 $112.7MFY23 $90.2MFY24 $83.3MFY25 $170.4M

Net Income

+14.6% YoY

$-193.9MFY 2025

FY22 $-280.3MFY23 $-263.5MFY24 $-227.1MFY25 $-193.9M

Operating Income

+30.9% YoY

$-161.2MFY 2025

FY22 $-262.9MFY23 $-268.1MFY24 $-233.3MFY25 $-161.2M

EPS (Diluted)

+18.1% YoY

$-3.76FY 2025

FY22 $-6.50FY23 $-6.02FY24 $-4.59FY25 $-3.76

Total Assets

-2.8% YoY

$453.0MFY 2025

FY22 $833.3MFY23 $574.0MFY24 $466.0MFY25 $453.0M

Op. Cash Flow

+28.4% YoY

$-124.0MFY 2025

FY22 $-207.5MFY23 $-218.4MFY24 $-173.1MFY25 $-124.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Revenue	$170.4M +104.5%	$83.3M -7.7%	$90.2M -19.9%	$112.7M -76.0%	$470.3M +204.3%	$154.6M
Net Income	$-193.9M +14.6%	$-227.1M +13.8%	$-263.5M +6.0%	$-280.3M -319.3%	$127.8M +214.9%	$-111.3M
Operating Income	$-161.2M +30.9%	$-233.3M +13.0%	$-268.1M -2.0%	$-262.9M -264.3%	$160.0M +234.2%	$-119.2M
EPS (Diluted)	$-3.76 +18.1%	$-4.59 +23.8%	$-6.02 +7.4%	$-6.50 -323.4%	$2.91 +197.7%	$-2.98
Total Assets	$453.0M -2.8%	$466.0M -18.8%	$574.0M -31.1%	$833.3M -25.2%	$1.11B +57.3%	$708.2M
Operating Cash Flow	$-124.0M +28.4%	$-173.1M +20.7%	$-218.4M -5.3%	$-207.5M -194.8%	$218.9M +504.9%	$-54.1M

AI Insight: RGNX Financial Trends

RGNX collapsed from Q1 2025 profitability to severe cash burn and equity depletion, with revenue cratering 93% by Q1 2026.

• Q1 2025 inflection reversed sharply: net income swung from +$6M profit to -$90M loss in Q1 2026; operating cash burn accelerated to -$76M.

• Equity eroded 92% from $348M (Q2 2024) to $21M (Q1 2026); quarterly revenue collapsed from $89M (Q1 2025) to $6M (Q1 2026).

• Operating margins turned deeply negative: Q1 2025 showed +13% op margin; Q1 2026 slid to -1,383% as revenue imploded.

⚠ Equity now critically depleted at $21M; at current burn rate (-$76M Op CF in Q1 2026), runway is <1 quarter without capital raise.

⚠ Q1 2025 profitability appears to have been a one-quarter anomaly; no sustainable revenue or margin recovery evident in subsequent quarters.

AI Insight: RGNX Ratio Trends

REGNXBIO swung from profitability in Q1 2025 to severe operating losses in subsequent quarters, with Q4 2025 operating margin at -190%.

• Q1 2025 showed profitability: 13.6% operating margin, 6.8% NPM, 17.7% ROIC. Sharp reversal began Q2 2025.

• Operating margin deteriorated from 13.6% (Q1 2025) to -176.3% (Q3 2025) to -190.0% (Q4 2025). ROA collapsed to -59.3% by Q4 2025.

⚠ Q1 2025 profitability was isolated; subsequent 3 quarters show deepening losses. Root cause of Q2–Q4 2025 collapse unclear from metrics alone.

⚠ TTM ROA of -84.8% indicates cumulative operating stress. Q1 2026 data absent; recovery trajectory unknown.

Get alerted when RGNX's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for REGENXBIO Inc. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of RGNX

BlackRock, Inc.
$48.5M5,782,808 sh
Redmile Group, LLC
$36.6M4,368,804 sh
STATE STREET CORP
$22.9M2,731,485 sh
EverSource Wealth Advisors, LLC
$20.2M79,634 sh
MORGAN STANLEY
$17.3M2,066,157 sh
VANGUARD CAPITAL MANAGEMENT LLC
$16.8M2,007,146 sh
GOLDMAN SACHS GROUP INC
$15.4M1,839,463 sh
Integral Health Asset Management, LLC
$12.6M1,500,000 sh
Qube Research & Technologies Ltd
$11.0M1,310,493 sh
GEODE CAPITAL MANAGEMENT, LLC
$9.5M1,137,498 sh

Fund	Value	Shares
BlackRock, Inc.	$48.5M	5,782,808
Redmile Group, LLC	$36.6M	4,368,804
STATE STREET CORP	$22.9M	2,731,485
EverSource Wealth Advisors, LLC	$20.2M	79,634
MORGAN STANLEY	$17.3M	2,066,157
VANGUARD CAPITAL MANAGEMENT LLC	$16.8M	2,007,146
GOLDMAN SACHS GROUP INC	$15.4M	1,839,463
Integral Health Asset Management, LLC	$12.6M	1,500,000
Qube Research & Technologies Ltd	$11.0M	1,310,493
GEODE CAPITAL MANAGEMENT, LLC	$9.5M	1,137,498

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put RGNX on your watchlist

Track score changes the day REGENXBIO Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is RGNX a good stock to buy?

13F Pro's AI-powered analysis of REGENXBIO Inc. (RGNX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for RGNX are available on the RGNX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own RGNX?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling RGNX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of REGENXBIO Inc.'s investment landscape.